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Table I.
No significant differences were observed between the two groups. OR =
oocytes retrieved.
fer results obtained with HMG and rec-FSH. No differences
were observed in the two groups of patients.
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Introduction: The objective of the study was to assess the
efficacy and efficiency of a fixed daily dose of recombinant
follicle stimulating hormone, Follitropinum ~ (rFSH; 150 IU,
3 ampoules of 50 IU; Puregon'", NV Organon) and highly
purified urinary FSH (uFSH HP; 225 IU, 3 ampoules of 75
IU; Metrodin Hp®; Ares -Serono SA) in a fixed daily dose
regimen in in-vitro fertilization (IVF) and intracytoplasmic
sperm injection (ICSI) patients based upon the assumption
that the bioactivity of 50 IU of rFSH is in the range of the
bioactivity of 75 IU of FSH HP.
Materials and methods: A total of 148 subjects were included
in an open, randomized, group-comparative, bi-centre study.
All women were between 18-39 years of age (rFSH mean
31.8 ± 3.6 and FSH HP 31.9 ± 3.4), had regular cycles and
a BMI between 18-29 kg/m/. Male factor infertility was not
excluded. Prior to the start of FSH treatment the patients have
been treated by a gonadotrophin releasing hormone agonist
(s.c.) in a long down-regulation protocol. Stimulation with
FSH was done in a fixed dose regimen of rFSH 150 IU or
FSH HP 225 IV. Criterion for human chorionic gonadotrophin
administration (5000 or 10 000 IV) was the presence of 2-3
follicles ~ 17 mm according to hospital routine. All statistical
analyses were done on an intent-to-treat basis using analysis of
variance and testing for group differences adjusting for centres.
Results: Patients were comparable with respect to mean age,
mean body mass index and duration and cause of infertility.
A total of 165 cycles have been performed; rFSH: 89, FSH
HP: 76. The incidence of cycle cancellations (42; rFSH: 19,
FSH HP: 23) was comparable between the two treatment
groups. The treatment outcome (mean adjusted for centre ±
Results: The serum LH and FSH level increased rapidly after
injection of first GnRHa. The FSH level reached peak (27.53
± 6.34 lUll) in 5 h while LH level reached peak (34.35 ±
7.18 lUll) in 4 h. The flare of gonadotrophins persisted even
after second and third day injection of GnRHa, although the
peak levels were not as high as first injection (19. 56 ± 3.74
lUll in second day, 9.15 ± 1.29 lUll in third day for FSH;
32.18 ± 8.12 lUll in second day, 13.59 ± 1.04 lUll in third
day for LH). The down-regulation of gonadotrophin was
established in 4 days. The oestradiol level increased for 3 days
then decreased. When GnRHa was given for 7 days, the
gonadotrophin levels began to rise 6 days after last injection;
when given for 3 days, the gonadotrophin levels began to rise
3 days after last injection.
Conclusion: Even with ultra-low dose of GnRHa, the down-
regulation of gonadotrophin could be achieved. The flare-up
of gonadotrophin would persist for 3 days with this dose. The
duration of down-regulation was influenced by the duration of
GnRHa administration. In conclusion, 5 ug of triptorelin may
be used as an ovarian stimulation protocol with adjustment of
duration of administration.
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Introduction: This multicentric randomized prospective study
was designed to compare in ovarian stimulation and in-
vitro fertilization (IVF)-embryo transfer the use of human
menopausal gonadotrophin (HMG) and recombinant follicle
stimulating hormone (rec-FSH) in the single dose gonadotro-
phin releasing hormone (GnRH) antagonist (Cetrorelix)
protocol.
Materials and methods: Sixty-two infertile patients between
23 and 39 years old, with normal menstrual cycle and no more
than three previous IVF attempts, were included in the study.
The single dose of 3 mg Cetrorelix was injected in the late
follicular phase. HMG (n == 31) or rec-FSH (n == 31) were
randomly attributed and started on cycle day 2 with 2 ampoules
per day. Monitoring of the cycles was done with daily oestradiol
and luteinizing hormone and ultrasounds.
Results: The IVF-embryo transfer results (mean values) are
presented in Table I.
Conclusion: The majority of the studies published so far with
GnRH antagonists have been performed using HMG for
ovarian stimulation. In this study we compared, in the single
dose antagonist administration protocol, the IVF-embryo trans-
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SD) showed no significant differences between the groups,
e.g. treatment days: rFSH, 11.2 :±: 2.3; FSH HP, 11.0 :±: 1.8;
no. of ampoules used: 33.0 :±: 6.5, 32.6 :±: 5.4; oocytes
retrieved: 9.1 ± 5.1, 11.9 ± 7.3; mature oocytes: 7.7 ± 4.3,
10.0 ± 6.5; embryos obtained: 5.6 ± 3.3, 7.3 ± 5.3; type II
II embryos obtained: 5.4 ± 3.5,7.1 ± 5.4; embryos replaced:
2.0 ± 0.4, 2.0 ± 0.5; pregnancy rate/started cycle: 23/
80 (28.8%), 16/72 (22.2%); pregnancy rate/transfer: 23/70
(32.9%), 16/53 (30.2%); incidence of ovarian hyperstimulation
syndrome: 3/85 (3.5%), 3/68 (4.4%) respectively. The dosage
of FSH activity based upon the no. of ampoules used was
1650 IV (± 421 IV) rFSH and 2445 IV (± 477 IV) FSH HP.
This difference is highly significant (P < 0.0001).
Conclusion: The clinical efficacy of the rFSH 150 IV equals
the efficacy of FSH HP 225 IV. These results suggest that
1 IV of rFSH is not identical to 1 IV FSH HP as shown by
the significant reduction of the total dosage per cycle of 795 IV
in the rFSH group. With the introduction of recombinant
hormones such as Follitropinum p, the classical standardization
of 1 IV has become questionable.
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Introduction: Our objective was to determine whether an
ovarian stimulation regimen which involves gonadotrophin-
releasing hormone analogue (GnRHa) discontinuation prior to
administration of gonadotrophins would benefit poor respond-
ers to a conventional continuous down-regulation ovarian
stimulation protocol.
Material and methods: Sixty-three patients with either previ-
ous poor response to ovarian stimulation and/or high basal
follicle stimulation hormone (FSH) level (~9 mIV/ml) under-
going 78 in-vitro fertilization (IVF)-embryo transfer cycles
were randomly assigned to twa. groups. In all patients ovarian
down-regulation by administration of GnRHa started in mid-
luteal phase. Whereas in the study group (40 cycles) it ended
before administration of gonadotropins (interrupted regimen),
in controls (38 cycles) GnRHa treatment was continued
throughout the follicular phase.
Results: Significantly higher cancellation rate was noted in
the interrupted regimen group compared to controls .(22.5%
versus 5%, respectively; P < 0.05). Both interrupted and
control regimens resulted in similar stimulation characteristics,
and clinical pregnancy rates per embryo transfer (11% versus
10.3%, respectively, P = non-significant). In 13 patients
with basal follicle stimulating hormone (FSH) that was not
persistently high, the interrupted regimen resulted in signific-
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andy higher number of retrieved oocytes compared to standard
'long' protocol (7.6 ± 1.03 versus 4.0 ± 0.68, respectively,
P < 0.05).
Conclusions: Whereas for most low responders cessation of
GnRHa treatment upon down-regulation offers no further
advantage, by meticulous individualization of its application
it may confer a benefit for a subset of patients with adequate
ovarian reserve as evidenced by basal FSH level that is not
persistently high.
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Introduction: Since recombinant gonadotrophins are highly
purified (>99.9%) and can be administered subcutaneously,
local tolerance to injections should be similar between the
two available products: Gonal-P® and Puregon", However,
anecdotal reports at the time suggested that Puregon was less
well tolerated by patients compared to Gonal-F. This study
was designed to confirm or refute these reports.
Materials and methods: A total of 39 patients who had up
to two previous cycles of in-vitro fertilization (IVF) were
randomized into the study: Gonal-F 20 patients and Puregon
19 patients. Following long down-regulation (600 ug intranasal
nafarelin from day 21) 150 IV per day gonadotrophin was
administered (2 ampoules of 75 IV Gonal-F or 1 ampoule
each of 50 IV and 100 IV Puregon). Patients or their partners
were shown how to administer their injections. Tolerability
(pain, burning, itching redness and bruising) to each injection
was recorded on a diary card. Ovarian response was assessed
by ultrasound monitoring and human chorionic gonadotrophin
(10 000 IV) was given with at least one follicle ~20 mm and
two others > 16 mm
Results: Local reactions were compared between treatments
from day 2 until the end of cycle. Two patients in the Gonal-
F group did not return their diary cards, therefore data are
presented on 18 patients. The day 1 injection was excluded
from the analysis to remove any learning curve from the
injection procedure. Interim data are shown and complete data
will be presented with statistical comparisons. In the Gonal-F
group the proportion of the treatment cycle which was symp-
tom-free (all symptoms) was 40.7% compared to 8.8% for
Puregon patients. Data also suggest that a greater proportion
of injections led to moderate or severe reactions with Puregon
than Gonal-F (Table I), most clearly demonstrated for pain
and burning. Also, more patients in the Puregon group reported
reactions with a maximum severity of moderate or severe than
Gonal-F patients, with pain and burning being the most
common (Table II).
